Mulmit

GENELUX CorpGENELUX Corp

GNLX Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2025-12-318,000-33,214,000-32,145,000-0.86
2024-12-318,000-31,696,000-29,869,000-0.95
2023-12-31170,000-24,165,000-28,297,000-1.16
2022-12-3111,068,000-3,013,000-5,207,000-0.57

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-08-31Cappello JosephChief Technical Officer10,257
2026-08-31Zindrick ThomasPresident and CEO34,463
2026-08-31Yu YongChief Scientific Officer9,683
2026-08-04Yu YongChief Scientific Officer653
2026-08-04Cappello JosephChief Technical Officer653
2026-08-04Zindrick ThomasPresident and CEO3,023
2026-07-01Smither John W12,000
2026-06-16Pulisic MatthewChief Financial Officer278,906
2026-06-16Groen EricGeneral Counsel233,957
2026-06-16Cappello JosephChief Technical Officer174,841
2026-06-16Tyree James L28,409
2026-06-16Tyree James L31,566

8-K events

FiledItems
2026-06-22Submission of matters to a vote
2026-03-19Entry into a material agreement · Financial statements and exhibits
2026-02-02Regulation FD disclosure · Financial statements and exhibits
2026-01-08Other events · Financial statements and exhibits
2026-01-05Regulation FD disclosure · Other events · Financial statements and exhibits
2026-01-02Officer or director change · Financial statements and exhibits
2025-09-03Officer or director change · Submission of matters to a vote
2025-03-25Other events · Financial statements and exhibits
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…

Pharmaceutical Preparations — 같은 업종, 그리고 규모가 비슷한 기업Pharmaceutical Preparations — and other companies of a similar size

SEC가 같은 업종(Pharmaceutical Preparations)으로 분류한 기업이 먼저 오고, 그다음은 제출된 매출로 가까운 순입니다 — 가장 최근 연간 값이며, 연간 값이 없으면 최근 네 분기 합입니다. Companies the SEC assigns to the same industry (Pharmaceutical Preparations) come first, then the nearest by revenue as filed — the latest annual figure, or the last four quarters where no annual one is filed. 순서일 뿐 값이 싸거나 비싸다는 뜻이 아닙니다.Order only — it does not say a company is cheap or expensive.